Literature DB >> 2254725

Bartter's syndrome and diabetes mellitus.

G Venkat Raman1, J D Albano, J G Millar, H A Lee.   

Abstract

We here report a case of Bartter's syndrome occurring in association with diabetes mellitus. The patient, an insulin-dependent diabetic, presented with hypokalaemia, inappropriate kaliuresis and metabolic alkalosis. He had high plasma renin activity, relatively low plasma aldosterone, and resistance to infused angiotensin II. A high potassium diet raised total body potassium and serum potassium, did not affect plasma renin activity, but raised plasma aldosterone significantly and did not alter the resistance to angiotensin II. Indomethacin administered acutely reduced urinary potassium and kallikrein excretion and, on chronic administration, lowered plasma renin activity, urinary chloride excretion, and raised serum potassium. Salt restriction resulted in a prompt and significant reduction in urinary sodium and chloride excretion. Urinary kallikrein excretion was very high throughout, increased with sodium restriction, and decreased with sodium loading. Oral potassium supplementation partially corrected the hypokalaemia, but did not affect blood sugar control. In this patient the primary defect appears to have been primary urinary potassium wasting, rather than sodium or chloride wasting. The striking effects of indomethacin suggest that prostaglandins may play a fundamental role in the genesis of the syndrome.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2254725     DOI: 10.1111/j.1365-2796.1990.tb00273.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  2 in total

Review 1.  The pathophysiological and molecular basis of Bartter's and Gitelman's syndromes.

Authors:  S Bhandari
Journal:  Postgrad Med J       Date:  1999-07       Impact factor: 2.401

2.  Bartter syndrome-like phenotype in a patient with diabetes: a case report.

Authors:  Chamara Dalugama; Manoji Pathirage; S A M Kularatne
Journal:  J Med Case Rep       Date:  2018-08-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.